Literature DB >> 9814993

Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin.

D Agnello1, R Bertini, S Sacco, C Meazza, P Villa, P Ghezzi.   

Abstract

Urocortin (UCN) is a neuropeptide homologous with corticotropin-releasing factor (CRF), which has anti-inflammatory activities not all mediated by corticosteroids. In mice, UCN (1 microg/mouse sc) significantly reduced lipopolysaccharide (LPS)-induced serum tumor necrosis factor (TNF) and interleukin (IL)-1beta levels in vivo but did not affect serum IL-6. These effects were paralleled by a rise in corticosterone (CS) levels. Blockade of the CS increase by cyanoketone did not prevent TNF inhibition by UCN, suggesting the neuropeptide has anti-inflammatory mechanisms independent of the hypothalamus-pituitary-adrenal axis. In fact UCN had a direct inhibitory effect on LPS-induced TNF in rat Kupffer cells at concentrations between 10(-10) and 10(-16) M, and this effect was related to increased cAMP levels. However, the in vivo inhibition of LPS-induced IL-1beta by UCN was reversed by cyanoketone, indicating that the increase of endogenous glucocorticoids might be more important in IL-1beta inhibition than in TNF inhibition by UCN.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814993     DOI: 10.1152/ajpendo.1998.275.5.E757

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

1.  Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas.

Authors:  Serenat Eris Yalcin; Irfan Ocal; Yakup Yalcin; Halime Sen Selim; Melike Demir Caltekin; Huseyin Aydogmus; Sefa Kelekci
Journal:  Eurasian J Med       Date:  2017-06

2.  Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response.

Authors:  Elena Gonzalez-Rey; Alejo Chorny; Nieves Varela; Gema Robledo; Mario Delgado
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

3.  Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum.

Authors:  Susanne E la Fleur; Elizabeth C Wick; Prema S Idumalla; Eileen F Grady; Aditi Bhargava
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-09       Impact factor: 11.205

4.  Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease.

Authors:  E Gonzalez-Rey; A Fernandez-Martin; A Chorny; M Delgado
Journal:  Gut       Date:  2006-01-09       Impact factor: 23.059

5.  Urocortins and CRF type 2 receptor isoforms expression in the rat stomach are regulated by endotoxin: role in the modulation of delayed gastric emptying.

Authors:  Pu-Qing Yuan; S Vincent Wu; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-04-19       Impact factor: 4.052

Review 6.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

7.  Urocortins and CRF receptor type 2 variants in the male rat colon: gene expression and regulation by endotoxin and anti-inflammatory effect.

Authors:  Pu-Qing Yuan; S Vincent Wu; Charalabos Pothoulakis; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-07       Impact factor: 4.052

8.  Local secretion of urocortin 1 promotes microvascular permeability during lipopolysaccharide-induced inflammation.

Authors:  Elizabeth L Cureton; Alexander Q Ereso; Gregory P Victorino; Brian Curran; Daniel P Poole; Min Liao; Alden H Harken; Aditi Bhargava
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

9.  Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness.

Authors:  Ariadne Androulidaki; Erini Dermitzaki; Maria Venihaki; Effie Karagianni; Olga Rassouli; Erini Andreakou; Christos Stournaras; Andrew N Margioris; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2009-06-02       Impact factor: 27.401

Review 10.  Bench-to-bedside review: the value of cardiac biomarkers in the intensive care patient.

Authors:  Anthony S McLean; Stephen J Huang; Mark Salter
Journal:  Crit Care       Date:  2008-06-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.